![[current-page:title] logo](/sites/default/files/styles/logo/public/default_images/_no-logo.png?itok=8OH0tuUw){kind=logo}
Corporate information
Registration country
Funding rounds
Acquisition USD 20,000,000,000
USD 20,000,000,000 ( ) at USD 20,000,000,000 pre-money valuation
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Sanofi Aventis | USD 20,000,000,000 (USD 20,000,000,000) Initial investment. |
Actual initial investment stage
Series B (1)
Investment activity status
Active investor
Selected investments
Displaying 1 - 5 of 5| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
|
|
Bluebird Bio Inc | Developer of an innovative gene therapies for severe genetic disorders | Series B | |||
|
|
GelTex Pharmaceuticals | Acquisition 1,000,000,000 (USD 1,000,000,000) | ||||
|
|
ILEX Oncology Inc | N/A | ||||
|
|
Sirtris Pharmaceuticals Inc | Series C | ||||
|
Fate Therapeutics Inc | Series B Initial investment |